| PATENT REGISTER | ||||||||||||||||||||||||
| A Supplementary Protection Certificate (SPC) exists for this Patent. To view the SPC Details click following SPC number(s): 2015/052 2015/053 2015/054 2016/057 2016/058 | ||||||||||||||||||||||||
| Status | Expired | Patent No. | 1663240 | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Application No. | 04787096.9 | Date of Filing | 03/09/2004 | |||||||||||||||||||||
| Date Grant Published | 22/04/2015 | Application Published | 07/06/2006 | |||||||||||||||||||||
| Title of Invention | COMBINATIONS OF A PYRIMIDINE CONTAINING NNRTI WITH RT INHIBITORS | |||||||||||||||||||||||
| Priority |
|
|||||||||||||||||||||||
| Inventor | STOFFELS, Paul | |||||||||||||||||||||||
| Current Proprietor |
JANSSEN SCIENCES IRELAND UNLIMITED COMPANY Barnahely Ringaskiddy Co Cork IRELAND |
|||||||||||||||||||||||
| Address for service |
RWS TRANSLATIONS 44-46 Rue Alphonse Penaud PARIS 75020 FRANCE |
|||||||||||||||||||||||
| Renewal Fees |
|
|||||||||||||||||||||||
| Publication Language | English | |||||||||||||||||||||||
| Translation Received Date | ||||||||||||||||||||||||
| 13/07/2015 | Address for Service recorded as RWS TRANSLATIONS, Europa House, Chiltern Park, Chiltern Hill, Chalfont St Peter, Bucks SL9 9FG, United Kingdom received on 07/07/2015. | |||||||||||||||||||||||
| 28/10/2015 | Request for grant a Supplementary Protection Certificate, citing Patent number 1663240 as the relevant basic patent, in respect of the product A combination of rilpivirine or a therapeutically equivalent form thereof protected by the basic patent, such as a pharmaceutically acceptable salt of rilpivirine, including the hydrochloride salt of rilpivirine, and emtricitabine filed on 21/10/2015. Reference number of request is 2015/052. | |||||||||||||||||||||||
| 28/10/2015 | Request for grant a Supplementary Protection Certificate, citing Patent number 1663240 as the relevant basic patent, in respect of the product A combination of rilpivirine or a therapeutically equivalent form thereof protected by the basic patent, such as a pharmaceutically acceptable salt of rilpivirine, including the hydrochloride salt of rilpivirine, tenofovir, in particular tenofovir disproxil fumarate, and emtricitabine filed on 21/10/2015. Reference number of request is 2015/053. | |||||||||||||||||||||||
| 28/10/2015 | Request for grant a Supplementary Protection Certificate, citing Patent number 1663240 as the relevant basic patent, in respect of the product A combination of rilpivirine or a therapeutically equivalent form thereof protected by the basic patent, such as a pharmaceutically acceptable salt of rilpivirine, including the hydrochloride salt of rilpivirine, and tenofovir, in particular disproxil fumarate filed on 21/10/2015. Reference number of request is 2015/054. | |||||||||||||||||||||||
| 03/01/2017 | Request for grant a Supplementary Protection Certificate, citing Patent number 1663240 as the relevant basic patent, in respect of the product A combination of: rilpivirine or a therapeutically equivalent form thereof protected by the basic patent, such as a pharmaceutically acceptable salt of rilpivirine, including the hydrochloride salt of rilpivirine; and tenofovir alafenamide, or a pharmaceutically acceptable salt thereof, in particular tenofovir alafenamide fumarate. filed on 20/12/2016. Reference number of request is 2016/057. | |||||||||||||||||||||||
| 03/01/2017 | Request for grant a Supplementary Protection Certificate, citing Patent number 1663240 as the relevant basic patent, in respect of the product A combination of: rilpivirine or a therapeutically equivalent form thereof protected by the basic patent, such as a pharmaceutically acceptable salt of rilpivirine, including the hydrochloride salt of rilpivirine; emtricitabine; and tenofovir alafenamide or a pharmaceutically acceptable salt thereof, in particular tenofovir alafenamide fumarate. filed on 20/12/2016. Reference number of request is 2016/058. | |||||||||||||||||||||||
| 01/02/2018 | Supplementary Protection Certificate Number 2015/052, having an expiry date of 27/11/2026 granted on 01/02/2018. | |||||||||||||||||||||||
| 01/02/2018 | Supplementary Protection Certificate Number 2015/053, having an expiry date of 27/11/2026 granted on 01/02/2018. | |||||||||||||||||||||||
| 01/02/2018 | Supplementary Protection Certificate Number 2015/054, having an expiry date of 27/11/2026 granted on 01/02/2018. | |||||||||||||||||||||||
| 13/10/2020 | Change of Address for Service from RWS TRANSLATIONS, Europa House, Chiltern Park, Chiltern Hill, Chalfont St Peter, Bucks SL9 9FG, United Kingdom to RWS TRANSLATIONS, 2, rue Sainte Victoire, 78000 Versailles, France recorded on 08/10/2020 | |||||||||||||||||||||||
| 21/01/2022 | Request for grant of Supplementary Protection Certificate No. 2016/057 withdrawn on 21/01/2022. | |||||||||||||||||||||||
| 21/01/2022 | Request for grant of Supplementary Protection Certificate No. 2016/058 withdrawn on 21/01/2022. | |||||||||||||||||||||||
| 02/03/2023 | Amendment of patent specification as a result of opposition proceedings at the EPO on 01/03/2023 | |||||||||||||||||||||||
| 30/05/2023 | Change of Address for Service from RWS TRANSLATIONS, 2, rue Sainte Victoire, 78000 Versailles, France to RWS TRANSLATIONS, 44-46 Rue Alphonse Penaud, PARIS 75020, France recorded on 26/05/2023 | |||||||||||||||||||||||
| 31/05/2023 | Change of name and address of proprietor from Janssen Sciences Ireland UC, Eastgate Village, Eastgate, Little Island, County Cork, Ireland to JANSSEN SCIENCES IRELAND UNLIMITED COMPANY, Barnahely, Ringaskiddy, Co Cork, Ireland recorded on 23/05/2023. | |||||||||||||||||||||||
| 01/10/2024 | Patent expired on 02/09/2024. | |||||||||||||||||||||||
